Parasitology Research

, Volume 105, Issue 4, pp 899–906

Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use

  • Rashad A. Abdul-Ghani
  • Naguiba Loutfy
  • Azza Hassan


Schistosomiasis is a chronic parasitic disease affecting about 207 million people in the world. It still represents a major health problem in many tropical and sub-tropical countries as well as for travelers from developed countries. Control of the disease depends mainly on chemotherapy, with praziquantel becoming the exclusive drug. Extensive use of praziquantel with concerns about the possibility of drug resistance development, unavailability of an applicable vaccine, and the absence of a reasonable alternative to praziquantel all represent a real challenge. One of the suggested solutions is to exploit the advantages of compounds that proved efficacious at the experimental level with a good safety profile. These may undergo further investigations for the sake of developing their antischistosomal properties or to incorporate them in combination therapies. Chemotherapy literature is redundant with a huge number of compounds screened for their schistosomicidal properties. However, only a few of these may act as drug leads that could be promising in the development of a therapeutic reserve for schistosomiasis. The present paper reviews previous studies carried out on some of these compounds.


  1. Abdulla MH, Lim KC, Sajid M, McKerrow JH, Caffrey CR (2007) Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med 4:e14PubMedCrossRefGoogle Scholar
  2. Alger HM, Williams DL (2002) The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol Biochem Parasitol 121:129–139PubMedCrossRefGoogle Scholar
  3. Ambroso JL, Harris C (1994) In vitro embryotoxicity of the cysteine proteinase inhibitors benzyloxycarbonyl-phenylalanine-alanine-diazomethane (Z-Phe-Ala-CHN2) and benzyloxycarbonyl-phenylalanine-phenylalanine-diazomethane (Z-Phe-Phe-CHN2). Teratology 50:214–228PubMedCrossRefGoogle Scholar
  4. Ansseau M, Doumont A, Thiry D, von Frenckell R, Collard J (1985) Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design. Psychoparmacology 87:130–135CrossRefGoogle Scholar
  5. Baard AP, Sommers DK, Honiball PJ, Fourie ED, du Toit LE (1979) Preliminary results in human schistosomiasis with Ro 11-3128. S Afr Med J 55:617–618PubMedGoogle Scholar
  6. Bennett JL (1980) Characteristics of antischistosomal benzodiazepine binding sites in Schistosoma mansoni. J Parasitol 66:742–747PubMedCrossRefGoogle Scholar
  7. Bergquist NR, Colley DG (1998) Schistosomiasis vaccine: research to development. Parasitol Today 14:99–104PubMedCrossRefGoogle Scholar
  8. Bergquist R, Al-Sherbiny M, Barakat R, Olds R (2002) Blueprint for schistosomiasis vaccine development. Acta Trop 82:183–192PubMedCrossRefGoogle Scholar
  9. Bickle QD, Sacko M, Vignali DA (1990) Induction of immunity against Schistosoma mansoni by drug (Ro11–3128)-terminated infections: analysis of surface antigen recognition. Parasite Immunol 12:569–586PubMedCrossRefGoogle Scholar
  10. Botros SS, Bennett JL (2007) Praziquantel resistance. Expert Opin Drug Discov 2:S35–S40CrossRefGoogle Scholar
  11. Bricker CS, Depenbusch JW, Bennett JL, Thompson DP (1983) The relationship between tegumental disruption and muscle contraction in Schistosoma mansoni exposed to various compounds. Z Parasitenkd 69:61–71PubMedCrossRefGoogle Scholar
  12. Caffrey CR (2007) Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 11:433–439PubMedCrossRefGoogle Scholar
  13. Caffrey CR, McKerrow JH, Salter JP, Sajid M (2004) Blood ‘n’ guts: an update on schistosome digestive peptidases. Trends Parasitol 20:241–248PubMedCrossRefGoogle Scholar
  14. Capron A (1998) Schistosomiasis: forty years’ war on the worm. Parasitol Today 14:379–384PubMedCrossRefGoogle Scholar
  15. Cioli D (2005) Research towards new treatments for schistosomiasis. Report of the Scientific Working Group on Schistosomiasis, TDR/SWG/07, 70–75.
  16. Cioli D, Valle C, Angelucci F, Miele AE (2008) Will new antischistosomal drugs finally emerge? Trends Parasitol 24:379–382PubMedCrossRefGoogle Scholar
  17. Coelho PM, Pereira LH, de Mello RT (1995) Antischistosomal activity of acridanone-hydrazones in Cebus monkeys experimentally infected with the SJ strain of Schistosoma mansoni. Rev Soc Bras Med Trop 28:179–183PubMedGoogle Scholar
  18. Eichhold TH, Hookfin EB, Taiwo YO, De B, Wehmeyer KR (1997) Isolation and quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor. J Pharm Biomed Anal 16:459–467PubMedCrossRefGoogle Scholar
  19. Eshete F, Bennett JL (1990) Schistosoma mansoni: biochemical characteristics of the antischistosomal effects of Ro 15–5458. Exp Parasitol 71:69–80PubMedCrossRefGoogle Scholar
  20. Eshete F, Bennett JL (1991) The schistosomicidal compound Ro 15–5458 causes a reduction in the RNA content of Schistosoma mansoni. Mol Biochem Parasitol 45:1–8PubMedCrossRefGoogle Scholar
  21. Fenwick A, Webster JB (2006) Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis 19:577–582PubMedCrossRefGoogle Scholar
  22. Gromer S, Urig S, Becker K (2004) The thioredoxin system—from science to clinic. Med Res Rev 24:40–89PubMedCrossRefGoogle Scholar
  23. Gryseels B, Polman K, Clerinx J, Kestens L (2006) Human schistosomiasis. Lancet 368:1106–1118PubMedCrossRefGoogle Scholar
  24. Guirguis FR (2003) Efficacy of praziquantel and Ro 15–5458, a 9-acridanone-hydrazone derivative, against Schistosoma haematobium. Arzneimittelforschung 53:57–61PubMedGoogle Scholar
  25. Hagan P, Sharaf O (2003) Schistosomiasis vaccines. Expert Opin Biol Ther 3:1271–1278PubMedCrossRefGoogle Scholar
  26. Hunkeler W, Möhler H, Pieri L, Polc P, Bonetti EP, Cumin R, Schaffner R, Haefely W (1981) Selective antagonists of benzodiazepines. Nature 290:514–516PubMedCrossRefGoogle Scholar
  27. Kamel G, Metwally A, Guirguis F, Nessim NG, Noseir M (2000) Effect of a combination of the new antischistosomal drug Ro 15–5458 and praziquantel on different strains of Schistosoma mansoni infected mice. Arzneimittelforschung 50:391–394PubMedGoogle Scholar
  28. Katz N (1999) Schistosomiasis vaccines: the need for more research before clinical trials. Parasitol Today 15:165–167PubMedCrossRefGoogle Scholar
  29. Keiser J, Utzinger J, Tanner M, Dong Y, Vennerstrom JL (2006) The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica. J Antimicrob Chemother 58:1193–1197PubMedCrossRefGoogle Scholar
  30. King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365:1561–1569PubMedCrossRefGoogle Scholar
  31. Krauth-Siegel RL, Bauer H, Schirmer RH (2005) Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl 44:690–715PubMedCrossRefGoogle Scholar
  32. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arnér ES, Williams DL (2007) Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med 4:e206PubMedCrossRefGoogle Scholar
  33. Mahajan A, Kumar V, Mansour NR, Bickle Q, Chibale K (2008) Meclonazepam analogues as potential new antihelmintic agents. Bioorg Med Chem Lett 18:2333–2336PubMedCrossRefGoogle Scholar
  34. Mastin AJ, Wilson RA, Bickle QD (1985) Induction of resistance to Schistosoma mansoni in mice by chemotherapy: migration of schistosomula in primary and challenge infections. Parasitology 90:519–528PubMedCrossRefGoogle Scholar
  35. McKerrow JH, Engel JC, Caffrey CR (1999) Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg Med Chem 7:639–644PubMedCrossRefGoogle Scholar
  36. Metwally A, Abdel Hadi A, Mikhail EG, Aboú Shadi O, Sabry H, el-Nahal H (1997) Study of the efficacy of the new antischistosomal drug 10-[2-(diethylamino)ethyl]-9-acridanone-(thiazolidin-2-ylidene) hydrazone against an Egyptian strain of Schistosoma mansoni in mice. Arzneimittelforschung 47:975–979PubMedGoogle Scholar
  37. Noël F, Mendonça-Silva DL, Thibaut JP, Lopes DV (2007) Characterization of two classes of benzodiazepine binding sites in Schistosoma mansoni. Parasitology 134:1003–1012PubMedCrossRefGoogle Scholar
  38. Pax R, Bennett JL, Fetterer R (1978) A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch Pharmacol 304:309–315PubMedCrossRefGoogle Scholar
  39. Pereira LH, Coelho PM, Costa JO, de Mello RT (1995) Activity of 9-acridanone-hydrazone drugs detected at the pre-postural phase, in the experimental schistosomiasis mansoni. Mem Inst Oswaldo Cruz 90:425–428PubMedGoogle Scholar
  40. Pica-Mattoccia L, Dias LCD, Moroni R, Cioli D (1993) Schistosoma mansoni: genetic complementation analysis shows that two independent hycanthone/oxamniquine-resistant strains are mutated in the same gene. Exp Parasitol 77:445–449PubMedCrossRefGoogle Scholar
  41. Pica-Mattoccia L, Ruppel A, Xia CM, Cioli D (2008) Praziquantel and the benzodiazepine Ro 11–3128 do not compete for the same binding sites in schistosomes. Parasitology 135:47–54PubMedCrossRefGoogle Scholar
  42. Rollas S, Küçükgüzel SG (2007) Biological activities of hydrazone derivatives. Molecules 12:1910–1939PubMedCrossRefGoogle Scholar
  43. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ (1986) Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 61:294–303PubMedCrossRefGoogle Scholar
  44. Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL (2008) Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 14:407–412PubMedCrossRefGoogle Scholar
  45. Simeonov A, Jadhav A, Sayed AA, Wang Y, Nelson ME, Thomas CJ, Inglese J, Williams DL, Austin CP (2008) Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl Trop Dis 2:e127PubMedCrossRefGoogle Scholar
  46. Smith DA, Bickle QD, Kaye PM (1994) Resistance induced by drug abbreviated Schistosoma mansoni infections: treatment with the drug Ro11–3128 leads to enhanced antigen presentation. Immunology 82:419–426PubMedGoogle Scholar
  47. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6:411–425PubMedCrossRefGoogle Scholar
  48. Stohler HR (1978) Ro 11-3128, a novel schistosomicidal compound. In: Siegenthaler, W. and Lu¨thy, R. (Eds) Current Chemotherapy, Proceedings of the 10th Congress of Chemotherapy Vol. 1. American Society for Microbiology, Washington, pp. 147Google Scholar
  49. Stohler HR, Montavon M (1984) 9-Acridanone-hydrazones, a novel class of broad-spectrum schistosomicidal agents. In: Xl International Congress for Tropical Medicine and Malaria, Calgary, Canada, 16-22 September, p. 148, University of Calgary, CalgaryGoogle Scholar
  50. Sturrock RF, Bain J, Webbe G, Doenhoff MJ, Stohler H (1987) Parasitological evaluation of curative and subcurative doses of 9-acridanonehydrazone drugs against Schistosoma mansoni in baboons, and observations on changes in serum levels of anti-egg antibodies detected by ELISA. Trans R Soc Trop Med Hyg 81:188–192PubMedCrossRefGoogle Scholar
  51. Sulaiman SM, Ali HM, Homeida MM, Bennett JL (1989) Efficacy of a new Hoffmann-La Roche compound (Ro 15-5458) against Schistosoma mansoni (Gezira strain, Sudan) in vervet monkeys (Cercopithecus aethiops). Trop Med Parasitol 40:335–336PubMedGoogle Scholar
  52. Thibaut JP, Monteiro LM, Leite LC, Menezes CM, Lima LM, Noël F (2009) The effects of 3-methylclonazepam on Schistosoma mansoni musculature are not mediated by benzodiazepine receptors. Eur J Pharmacol 606:9–16PubMedCrossRefGoogle Scholar
  53. Utzinger J, Xiao S, N'Goran EK, Bergquist R, Tanner M (2003) The potential of artemether for the control of schistosomiasis. Int J Parasitol 31:1549–1562CrossRefGoogle Scholar
  54. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN (2004) Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430:900–904PubMedCrossRefGoogle Scholar
  55. Wasilewski MM, Lim KC, Phillips J, McKerrow JH (1996) Cysteine protease inhibitors block schistosome hemoglobin degradation in vitro and decrease worm burden and egg production in vivo. Mol Biochem Parasitol 81:179–189PubMedCrossRefGoogle Scholar
  56. WHO Expert Committee (2002) Prevention and control of schistosomiasis and soil-transmitted helminthiasis. WHO Tech Rep Ser 912: i–vi, 1–57Google Scholar
  57. Wood PJ, Mansour TE (1986) Schistosoma mansoni: serotonin uptake and its drug inhibition. Exp Parasitol 62:114–119PubMedCrossRefGoogle Scholar
  58. Xiao SH, Keiser J, Chollet J, Utzinger J, Dong Y, Endriss Y, Vennerstrom JL, Tanner M (2007) In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother 51:1440–1445PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Rashad A. Abdul-Ghani
    • 1
    • 2
  • Naguiba Loutfy
    • 2
  • Azza Hassan
    • 2
  1. 1.Department of Medical Parasitology, Faculty of Medicine and Health SciencesSana’a UniversitySana’aYemen
  2. 2.Tropical Health Department, High Institute of Public HealthAlexandria UniversityAlexandriaEgypt

Personalised recommendations